This glycoprotein hormone consists of 165 amino acids with four complex carbohydrate chains attached to it. Its role is to adjust the production of red blood cells to meet the oxygen demands of the tissues. Several studies have used the serum erythropoietin biomarkers to identify patients with traumatic brain injury, end-stage renal disease, and cancer. They are used for treating cancers and associated anemia, AIDS, and mostly in end-stage renal disorders (ESRD). There are five different type of epo biomarkers. Commercially used epo for humans is known as recombinant human erythropoietin (rHuEPO).
Rise in research and development in epo biomarker technology and growing prevalence of ESRD is projected to boost growth of the global epo biomarker market. For instance, in 2015, Molecular Health — a cloud-based healthcare decision support technology that aids in evidence-based treatment decisions and improved outcomes — confirmed the discovery that ephrin-type B receptor 4 (EPHB4) is an alternative epo receptor.
Get Free PDF Sample (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/4057
Market: Drivers
The epo biomarkers market is expected to witness significant growth over the forecast period, due to growing launch and adoption of erythropoietin alfa in cancer patients suffering from anemia. For instance, in November 2018, Pfizer launched epoetin alfa biosimilar — Retacrit — at 33% discounted rate than the original drug in the U.S. for treatment of anemia caused by chronic kidney disease and chemotherapy.
Moreover, growing prevalence of ESRD, which causes kidney failure is expected to again boost the market growth. According to the U.S. Renal Data System Annual Data Report of 2016, over 660,000 people in the U.S. were treated for kidney failure or ESRD. Out of these, 468,000 were dialysis patients and over 193,000 had a functioning kidney transplant.
Market: Restraints
Over-production of red blood cells due to over-expression of epo biomarkers, which leads to absolute polycythemia and other conditions is expected to hinder market growth. According to an article published in Biospace Journal in 2015, in the U.S. between 40% and 90% of cancer patients suffer from chemotherapy-induced anemia. Use of epo in cancer patients that suffer from chemotherapy-induced anemia was restricted by the Food and Drug Administration (FDA) due to increasing adverse events including decreased survival and increased risk of tumor progression and recurrence.
Ask for PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/4057
Market: Regional Analysis
North America is expected to hold a dominant position in the epo biomarkers market over the forecast period, due to well-established healthcare infrastructure and growing prevalence of cancer in the region. According to World Health Organization’s (WHO) 2018 report, around 609,640 deaths were recorded due to cancer and around 1.7 million new cases of cancer were diagnosed in 2018 in the U.S.
Asia Pacific is projected to experience significant growth in the epo biomarkers market, due to presence of major companies such as 3Sbio Group, Biocon Ltd., Genscript, Intas Pharmaceuticals Ltd., Kyowa Hakko Kirin Co., Ltd., and Shandong Kexing Bioproducts Co. Ltd. Moreover, growing prevalence of AIDS in India, China, Pakistan, and Bangladesh is also contributing to epo biomarker market growth. For instance, according to the UNAIDS Data 2018 for Asia Pacific region, in India 2.1 million people are living with HIV AIDS at the end of 2017.
Market: Competitive Landscape
Key players operating in the global epo biomarkers market include, 3Sbio Group, Agilent Technologies, Inc., Amgen Inc., Bioagilytix Labs, Biocon Ltd., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Galenica Ag, Genscript, Glaxosmithkline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., Kyowa Hakko Kirin Co., Ltd., Teva Pharmaceutical Industries Ltd., Merck Kgaa, Myriad Rbm, Novartis Ag, Pacific Biomarkers, Pfizer Inc., Shandong Kexing Bioproducts Co. Ltd., Siemens Ag, and Thermo Fisher Scientific.
Reasons to Buy this Epo Biomarkers Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Epo Biomarkers market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Epo Biomarkers market
➡Leading company profiles reveal details of key Epo Biomarkers market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Epo Biomarkers market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
https://www.coherentmarketinsights.com/promo/buynow/4057
Epo Biomarkers Market: Taxonomy
The global epo biomarker market is segmented on the basis of biomarker type, application, end user, and region.
By Biomarker Type
- Recombinant human erythropoietin
- Erythropoietin alfa
- Erythropoietin beta
- Erythropoietin zeta
- Erythropoietin theta
- Darbepoietin alfa
By Application
- End-Stage Renal Disorder
- Cancer
- Rheumatoid Arthritis
- AIDS
- Myelodysplastic Syndrome
- Neurology
- Hematology
- Others
By End User
- Diagnostic centers
- Hospitals
- Ambulatory care and surgical centers
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837